Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Metrics to compare | 42Z | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship42ZPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −6.2x | −0.7x | |
PEG Ratio | 0.00 | 0.14 | 0.00 | |
Price/Book | 0.0x | 5.3x | 2.6x | |
Price / LTM Sales | 0.0x | 42.4x | 3.4x | |
Upside (Analyst Target) | 0.0% | 155.1% | 37.9% | |
Fair Value Upside | Unlock | 1.8% | 5.2% | Unlock |